TMX-202
/ UroGen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 17, 2018
A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
(PubMed, World J Urol)
- "TMX-101 and TMX-202 are TLR-7 agonists with antitumor activity. Treatment with TMX-101 and TMX-202 resulted in less tumor-bearing rats compared to vehicle or saline control groups, although not statistically significant. In this aggressive bladder cancer model, a lower number of tumor-positive rats after treatment with TLR-7 agonists indicates activity for the treatment of non-muscle invasive bladder cancer."
Journal
1 to 1
Of
1
Go to page
1